Organ systems

Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress

Monday, May 17, 2021 - 9:05pm

The Company\xe2\x80\x99s lead clinical asset, RZ358, is in Phase 2b development for treatment of congenital hyperinsulinism (CHI), a rare pediatric endocrine disorder.

Key Points: 
  • The Company\xe2\x80\x99s lead clinical asset, RZ358, is in Phase 2b development for treatment of congenital hyperinsulinism (CHI), a rare pediatric endocrine disorder.
  • The Company is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment of diabetic macular edema.
  • Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain.
  • Accordingly, actual results may differ materially from anticipated results.

HempFusion Reports Q1, 2021 Financial Results

Monday, May 17, 2021 - 9:22pm

b'HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (\xe2\x80\x9cHempFusion\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), an industry leader in full spectrum cannabidiol (CBD) hemp extract wellness products and probiotics, today reported financial results for the first quarter ended March 31, 2021.

Key Points: 
  • b'HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (\xe2\x80\x9cHempFusion\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), an industry leader in full spectrum cannabidiol (CBD) hemp extract wellness products and probiotics, today reported financial results for the first quarter ended March 31, 2021.
  • Consolidated net revenue for the three months ended March 31, 2021 increased 7.6% quarter-over-quarter to $983,496 versus $913,646 in Q4-2020.
  • E-commerce accounted for 24.8% of net revenue in the first quarter of 2021 versus 16.8% for Q4, 2020.
  • HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations.

Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex for $32 Million

Monday, May 17, 2021 - 9:01pm

In 2017, Concert received a one-time cash payment of $160 million upon closing the asset purchase, with the potential for $90 million in future milestones.

Key Points: 
  • In 2017, Concert received a one-time cash payment of $160 million upon closing the asset purchase, with the potential for $90 million in future milestones.
  • Concert\xe2\x80\x99s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition.
  • Concert is also assessing a number of earlier-stage pipeline candidates.
  • We specifically disclaim any obligation to update any forward-looking statements included in this press release.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210517005838/en/\n'

FTC Announces Latest Enforcement Action Halting Deceptive CBD Product Marketing

Monday, May 17, 2021 - 10:03pm

The Federal Trade Commission today announced its latest law enforcement action to halt deceptive health and efficacy claims in the growing market for cannabidiol (CBD) products.

Key Points: 
  • The Federal Trade Commission today announced its latest law enforcement action to halt deceptive health and efficacy claims in the growing market for cannabidiol (CBD) products.
  • In addition, the complaint alleges the respondents falsely told consumers that scientific studies or research prove that CBD product effectively treat, mitigate, or cure the diseases, including hypertension, Parkinsons disease, and Alzheimers disease.
  • The proposed administrative order settling the FTCs chargescovers any dietary supplement, drug, or food product the respondents sell or market, including CBD products.
  • Finally, the order requires the respondents to pay the FTC $30,583.14the amount consumers paid Kushly for products sold using deceptive marketing.

FTC Announces Latest Enforcement Action Halting Deceptive CBD Product Marketing

Monday, May 17, 2021 - 10:02pm

The Federal Trade Commission today announced its latest law enforcement action to halt deceptive health and efficacy claims in the growing market for cannabidiol (CBD) products.

Key Points: 
  • The Federal Trade Commission today announced its latest law enforcement action to halt deceptive health and efficacy claims in the growing market for cannabidiol (CBD) products.
  • In addition, the complaint alleges the respondents falsely told consumers that scientific studies or research prove that CBD product effectively treat, mitigate, or cure the diseases, including hypertension, Parkinsons disease, and Alzheimers disease.
  • The proposed administrative order settling the FTCs chargescovers any dietary supplement, drug, or food product the respondents sell or market, including CBD products.
  • Finally, the order requires the respondents to pay the FTC $30,583.14the amount consumers paid Kushly for products sold using deceptive marketing.

Shady Grove Fertility (SGF) Chief Medical Officer, Eric Widra, M.D., Hosts Educational Polycystic Ovary Syndrome (PCOS) Session at the 2021 American Fertility Expo

Monday, May 17, 2021 - 9:30pm

b'ROCKVILLE, Md., May 17, 2021 /PRNewswire-PRWeb/ --Women seeking more information about polycystic ovary syndrome (PCOS) and its effects on fertility are welcomed to join Shady Grove Fertility (SGF) Chief Medical Officer, Eric Widra, M.D.

Key Points: 
  • b'ROCKVILLE, Md., May 17, 2021 /PRNewswire-PRWeb/ --Women seeking more information about polycystic ovary syndrome (PCOS) and its effects on fertility are welcomed to join Shady Grove Fertility (SGF) Chief Medical Officer, Eric Widra, M.D.
  • , for his breakout session on the topic at the virtual American Fertility Expo on May 22, 2021.
  • "I\'m proud to shed light on PCOS during the American Fertility Expo so that women can become empowered with answers regarding the condition and the treatment options available to them.
  • SGF is among the founding partner practices of US Fertility , the largest physician-owned, physician-led partnership of top-tier fertility practices in the U.S.

The Children’s Eye Foundation of AAPOS Debuts THE CURIOUS EYE: World’s First Interactive Storybook to Help Screen for Color Vision Deficiency

Monday, May 17, 2021 - 2:03pm

b"The Children\xe2\x80\x99s Eye Foundation of AAPOS today unveiled the world\xe2\x80\x99s first interactive children\xe2\x80\x99s book to help screen for color vision deficiency (CVD), commonly known as color blindness.

Key Points: 
  • b"The Children\xe2\x80\x99s Eye Foundation of AAPOS today unveiled the world\xe2\x80\x99s first interactive children\xe2\x80\x99s book to help screen for color vision deficiency (CVD), commonly known as color blindness.
  • View the full release here: https://www.businesswire.com/news/home/20210517005159/en/\nThe Children\xe2\x80\x99s Eye Foundation of AAPOS today unveiled the world\xe2\x80\x99s first interactive children\xe2\x80\x99s book to help screen for color vision deficiency (CVD), commonly known as color blindness.
  • \xe2\x80\x9cIt is a playful yet practical screening tool to help parents, educators, and eyecare professionals identify children who may have color vision deficiency early.
  • Follow the Children\xe2\x80\x99s Eye Foundation of AAPOS on Facebook , Instagram , and Twitter .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210517005159/en/\n"

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)

Monday, May 17, 2021 - 1:05pm

It is also licensed to Consilient Health Ltd. for the European Economic Area and United Kingdom, and Megapharm Ltd. for Israel and the Palestinian Authority.

Key Points: 
  • It is also licensed to Consilient Health Ltd. for the European Economic Area and United Kingdom, and Megapharm Ltd. for Israel and the Palestinian Authority.
  • Its level is often reduced in ALS patients and stimulation of GH excretion improves survival in ALS mouse models.
  • Dr. Steyn\xe2\x80\x99s research team at The University have confirmed these positive effects of ghrelin mimetics in several experiments.
  • Given the uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements.

Angela Bassett headlines Know Diabetes by Heart's virtual show from the Apollo Theater

Monday, May 17, 2021 - 1:30pm

But we also know education, advocacy and structural change can make a difference.

Key Points: 
  • But we also know education, advocacy and structural change can make a difference.
  • Whether you live with diabetes, love someone with diabetes or have lost someone to diabetes, heart disease or stroke, you\'ll relate to something in this show," Bassett said.
  • More than 122 million Americans have diabetes or prediabetes and are striving to manage their lives while living with the disease.
  • The American Diabetes Association (ADA) is the nation\'s leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive.

Attralus Announces Presentation of Clinical Data on AT-01, a Novel, Potential First-in-Class Diagnostic for Systemic Amyloidosis at the 2021 American College of Cardiology Annual Meeting

Monday, May 17, 2021 - 12:00pm

AT-01 is a novel diagnostic that provides the potential to change the treatment paradigm by enabling detection of all types of systemic amyloidosis at all stages of disease.\xe2\x80\x9d\nCurrently, there are no FDA-approved imaging agents as diagnostics for systemic amyloidosis.

Key Points: 
  • AT-01 is a novel diagnostic that provides the potential to change the treatment paradigm by enabling detection of all types of systemic amyloidosis at all stages of disease.\xe2\x80\x9d\nCurrently, there are no FDA-approved imaging agents as diagnostics for systemic amyloidosis.
  • Systemic amyloidosis is significantly underdiagnosed due to low awareness, lack of specific symptoms, and no current disease-specific diagnostics.
  • The two most common forms of systemic amyloidosis are immunoglobulin light-chain (AL) amyloidosis and transthyretin amyloidosis (ATTR).\nAttralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis.
  • By targeting the universal disease-causing pathology in systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.